5 Pharmaceutical Stocks to Buy Today According to Tiger Cub Billionaire Lee Ainslie

4. Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)

Maverick Capital’s Stake Value: $49,616,000
Percent of Maverick Capital’s 13F Portfolio: 0.46%
Number of Hedge Fund Holders: 33

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is a biopharmaceutical company that is focused on the discovery and development of RNAi therapeutics. The company’s RNAi-based medicines serve in four areas, such as genetic disorders, cardio-metabolic diseases, infectious diseases, and ocular diseases.

In Q2, Maverick Capital holds 292,683 shares in  Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), valued at $49.6 million. The company accounts for 0.46% of the fund’s 13F portfolio. In Q2 2021, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) posted an EPS of -$1.30 and revenue of $220.5 million presented a 112% year-over-year growth. Due to the strong quarter, the company lifted its FY21 guidance and now expects revenue of between $640 million to $655 million. Recently, Barclays raised its price target on Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) to $216, with an ‘Overweight’ rating on the shares. Since the beginning of the year, the stock has delivered a 56.8% return to shareholders.

As of Q2 2021, 33 hedge funds have positions in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), worth over $1.02 billion.